The companies are also running an open-label study to evaluate the long-term efficacy and safety of the psychedelic in ...

Assembly Biosciences has dosed the first subject in the Phase Ia/b study’s Phase Ib portion, evaluating ABI-1179.

Biogen has commenced dosing in the Phase III PROMINENT trial, assessing the efficacy and safety of the felzartamab drug.

INmune Bio said that a subset of Alzheimer's disease patients in the study showed clinical benefit from the therapy.

The endometriosis market is expected to grow from $938.0m in 2024 to $2.5 billion in 2034, at a compound annual growth rate ...

Amgen and Zai Lab have reported that the Phase III FORTITUDE-101 trial, assessing bemarituzumab with chemotherapy, achieved ...

The trial readout comes at a time of turbulence in the vaccine sector after RFK Jr replaced every member of the ACIP panel.

GRI Bio has announced encouraging six-week interim safety outcomes from the ongoing Phase IIa trial of GRI-0621.

Bio-Thera Solutions has commenced dosing in the randomised Phase III trial of the antibody-drug conjugate (ADC) BAT8006.

Pfizer has reported positive topline outcomes from the multicentre, open-label Phase III BASIS trial of Hympavzi.

Viatris’ presbyopia drug MR-141 (phentolamine ophthalmic solution 0.75%) has met the primary endpoint and all secondary ...

Lipocine has initiated subject dosing in a two-arm, blinded, randomised Phase III trial of LPCN 1154 for postpartum ...